Xcopri(Cenobamat) Side Effects

Discontinuation rates due to adverse effects range from 9% (200 mg) to 21% (400 mg).

Clinical and Postmarketing Safety Profile  

Common adverse reactions (≥10% incidence) include somnolence (19–37%), dizziness (18–33%), fatigue (12–24%), diplopia (6–15%), and headache (10%). Serious reactions include DRESS, hepatic failure (postmarketing), and QT interval shortening. Laboratory abnormalities include elevated ALT (>3× ULN in 2.7% at 400 mg) and hyperkalemia (up to 10.8%). Neuropsychiatric events (e.g., psychosis, aggression) and dependence/withdrawal symptoms (insomnia, tremor) are noted postmarketing. 

Cenobamat(Xcopri)
It is used for the treatment of partial-onset seizures in adults (with or without secondary generalized seizures).
RELATED ARTICLES
Effects and efficacy of Cenobamat

Cenobamate is a new type of anti-epileptic drug that exerts its therapeutic effect by acting on GABAA receptors....

Wednesday, July 2nd, 2025, 13:44
/ 1
1 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved